A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin
- 15 March 2013
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 75 (4), 966-978
- https://doi.org/10.1111/j.1365-2125.2012.04409.x
Abstract
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of edoxaban, an oral direct factor Xa inhibitor, in healthy subjects switching from warfarin. Seventy-two subjects were randomized to edoxaban 60 mg once daily (n = 48) or matching placebo (n = 24) for 5 days at 24 h after the last dose of warfarin treatment (INR 2.0 to 3.0). Safety/tolerability was the primary outcome measure. Pharmacokinetics, INR, aPTT, anti-FXa, thrombin generation and other coagulation assays were assessed. Seventy-two subjects were randomized and 64 subjects received at least one dose of edoxaban (n = 43) or placebo (n = 21) after achieving a target INR of 2.0 to 3.0 on warfarin treatment. Edoxaban 60 mg administered 24 h post-warfarin appeared to be safe and well tolerated. Adverse events were similar across treatments. For bleeding-related adverse events, eight subjects tested positive for faecal occult blood, five subjects during warfarin treatment and three subjects during edoxaban treatment. The mean (SD) baseline (post-dose of warfarin) INR was 2.31 (0.193) which increased to 3.84 (0.744) over 2 h during the edoxaban treatment (P < 0.0001 vs. placebo), returning to post-warfarin baseline within 12 h. A similar time course of effects for the other coagulation assays was observed in accordance with the drugs' mechanisms of action. In this study of healthy subjects, edoxaban administered 24 h after the last dose of warfarin was safe and well tolerated with transient increases across the various coagulation assays above post-warfarin baseline levels.Keywords
This publication has 15 references indexed in Scilit:
- Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxThrombosis and Haemostasis, 2011
- Facts and artefacts of coagulation assays for factor Xa inhibitorsThrombosis and Haemostasis, 2010
- Prothrombinase-Induced Clotting Time Assay for Determination of the Anticoagulant Effects of Unfractionated and Low-Molecular-Weight Heparins, Fondaparinux, and Thrombin InhibitorsAmerican Journal of Clinical Pathology, 2008
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Antithrombotic Therapy in Atrial FibrillationChest, 2008
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2008
- New Anticoagulants for Treatment of Venous ThromboembolismArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- New oral anticoagulants in atrial fibrillationEuropean Heart Journal, 2007
- Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.Int. Journal of Clinical Pharmacology and Therapeutics, 2007
- Effect of Study Setting on Anticoagulation ControlChest, 2006